Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1428P - Clinical benefit of combination chemo-immunotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic NSCLC

Date

21 Oct 2023

Session

Poster session 20

Topics

Cancer in Older Adults;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Thierry Landre

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

T. Landre1, N. Sadaoui2, D. Bouharati3, C. Taleb4

Author affiliations

  • 1 Ucog Dept., Hopital René Muret - AP HP, 93270 - Sevran/FR
  • 2 Geriatric, Assistance Publique - Hopitaux De Paris AP-HP, 75004 - Paris/FR
  • 3 Geriatric Oncology, Hopital René Muret - AP HP, 93270 - Sevran/FR
  • 4 Geriatric Oncology- Ucog, Hopital René Muret - AP HP, 93270 - Sevran/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1428P

Background

Anti-PD-1/PD-L1 plus chemotherapy (CT) is considered the standard of care in first line treatment of metastatic NSCLC. However, the clinical benefit of this combination in older patients is controversial.

Methods

We performed a meta-analysis (MA) of randomized trials that compared PD-1/PD-L1 inhibitor plus CT with CT alone in first line of treatment for older patients with advanced NSCLC. Subgroups of patients over 65 and over 75 were analyzed. The outcomes included overall survival (OS) and progression-free survival (PFS). A fixed-effect model was used.

Results

We analyzed 9 trials with an anti-PD-1 (camrelizumab, cemiplimab, nivolumab, pembrolizumab, tislelizumab or toripalimab) and 6 trials with an anti-PD-L1 (atezolizumab, durvalumab or sugemalimab), including 3371 patients (41%) over the age of 65 and 212 patients (<10%) over the age of 75. Most of the patients were men (65%), PS 0/1 (98%), PD-L1+ (66%) and smokers (82%). In patients >65 years, anti PD-(L)1 +/- CT was significantly associated (hazard ratio [95% confidence interval]) with prolonged OS (0.82 [0.74-0.91]; p = 0.0003) and PFS (0.65 [0.60-0.72]; p < 0.00001) compared to CT alone. Survival benefits occurred in both anti-PD-1 and anti-PD-L1 trials. For patients over 75 years of age, OS benefit was not statistically significant (0.80 [0.58-1.09]; p = 0.16).

Conclusions

For patients over the age of 65 with untreated NSCLC, the anti-PD-1/PD-L1 combination with CT, compared with CT alone, is associated with significantly improved OS and PFS. Due to the low number of patients it is difficult to conclude for those over 75.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.